Clinical Trial Update: A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010). [Phase 3]

View source ↗

Summary

This Phase 3 clinical trial compares Nemtabrutinib plus Venetoclax versus Venetoclax plus Rituximab in second-line or relapsed/refractory chronic lymphocytic le…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• Nemtabrutinib (nemtabrutinib)
• Rituximab (rituximab)
• Venetoclax (venetoclax)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Chronic Lymphocytic | Phase 3 | Status: RECRUITING